Holen Sie sich die Stockscreener-App
12.13
2.65%
-0.33
Handel nachbörslich:
12.19
0.06
+0.49%
Schlusskurs vom Vortag:
$12.46
Offen:
$12.49
24-Stunden-Volumen:
1.79M
Relative Volume:
1.18
Marktkapitalisierung:
$645.64M
Einnahmen:
$312.78M
Nettoeinkommen (Verlust:
$-143.56M
KGV:
-4.5093
EPS:
-2.69
Netto-Cashflow:
$1.22M
1W Leistung:
-7.40%
1M Leistung:
-39.74%
6M Leistung:
-51.17%
1J Leistung:
-56.07%
1-Tages-Spanne:
$12.03
$12.76
1-Wochen-Bereich:
$11.26
$12.76
52-Wochen-Spanne:
$10.96
$34.84
Caredx Inc Stock (CDNA) Company Profile
Firmenname
Caredx Inc
Sektor
Branche
Telefon
415-287-2300
Adresse
8000 MARINA BLVD, BRISBANE, CA
Vergleichen Sie CDNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CDNA
Caredx Inc
|
12.13 | 663.21M | 312.78M | -143.56M | 1.22M | -2.69 |
|
TMO
Thermo Fisher Scientific Inc
|
484.79 | 180.28B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.14 | 147.31B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
663.92 | 52.18B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
120.29 | 33.33B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.23 | 31.60B | 15.50B | 1.33B | 2.16B | 7.34 |
Caredx Inc Stock (CDNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Underweight |
| 2024-08-19 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-05-13 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-05-01 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-11-09 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-08-15 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-03-07 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2023-03-03 | Herabstufung | Craig Hallum | Buy → Hold |
| 2023-03-03 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2021-07-20 | Fortgesetzt | BTIG Research | Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-26 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-26 | Eingeleitet | BTIG Research | Buy |
| 2020-06-19 | Bestätigt | H.C. Wainwright | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-05-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2019-02-15 | Eingeleitet | Jefferies | Buy |
| 2018-10-23 | Fortgesetzt | Raymond James | Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Neutral |
| 2017-11-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-14 | Bestätigt | Mizuho | Buy |
| 2015-09-29 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-09-25 | Eingeleitet | Craig Hallum | Buy |
| 2015-03-18 | Bestätigt | Mizuho | Buy |
Alle ansehen
Caredx Inc Aktie (CDNA) Neueste Nachrichten
CareDx price target lowered to $22 from $26 at BTIG - TipRanks
CareDx stock price target lowered to $22 at BTIG on Medicare reimbursement concerns - Investing.com
CareDx's Q2 2025 Earnings: Unpacking Contradictions in EPIC Launch, Legal Settlements, and Volume Growth - AInvest
CareDx (CDNA): Analyst Lowers Price Target, Maintains Rating | C - GuruFocus
CareDx (CDNA) Price Target Cut to $14.00, Analyst Maintains 'Equal-Weight' Rating - AInvest
CareDx Reports Strong Growth in Testing Services - MSN
CareDx Inc. Reports Strong Growth Amid Challenges - The Globe and Mail
CareDx, Inc (NASDAQ:CDNA) Q2 2025 Earnings Call Transcript - Insider Monkey
CareDx Q2 2025 slides: 14% revenue growth despite analyst miss, EBITDA surges - Investing.com
How CareDx Inc stock performs during market volatility300% Return Stock Forecast - classian.co.kr
CareDx Publishes KOAR Study In American Journal of Transplantation, Showcasing AlloSure Dd-cfDNA For Enhanced Kidney Rejection Detection And Biopsy Guidance - 富途牛牛
CareDx secretary Novack sells $34,380 in shares - Investing.com
CareDx secretary Novack sells $34,380 in shares By Investing.com - Investing.com Australia
CareDx Appoints New CFO Amid Financial Growth - MSN
CareDx Faces Financial Challenges Amid Mixed Signals and Policy Uncertainties - TipRanks
CareDx 2025 Q2 Earnings EPS Beats Expectations, Net Loss Widens - AInvest
CareDx narrows 2025 revenue guidance to $367M-$373M as kidney surveillance protocols expand - MSN
CareDx Names Nathan Smith as Chief Financial Officer - MarketScreener
CareDx (CDNA) EPS Beats Sales Gain 14% - sharewise.com
Earnings call transcript: CareDx Q2 2025 misses revenue forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: CareDx Q2 2025 misses revenue forecasts - Investing.com
CareDx Q2 2025 Earnings: EPS of -$0.10 Meets Estimates, Revenue of $90.5 Million Slightly Misses Expectations - AInvest
CareDx Publishes Landmark KOAR Study on AlloSure Efficacy in Kidney Transplant Surveillance in American Journal of Transplantation. - AInvest
CareDx: Q2 Earnings Snapshot - Greenwich Time
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer - BioSpace
CareDx narrows 2025 revenue guidance to $367M-$373M as kidney surveillance protocols expand. - AInvest
CareDx Names Nathan Smith as New CFO - AInvest
Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings - Yahoo Finance
CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates - Yahoo Finance
CareDx Inc. Faces Q2 Loss with Revenue Below ExpectationsNews and Statistics - IndexBox
CareDx's Strategic Leadership Shift: How CFO Nathan Smith's Appointment Signals a New Era of Growth - AInvest
Caredx Inc earnings beat by $0.20, revenue fell short of estimates - Investing.com South Africa
CareDx narrows FY25 revenue view to $367M-$373M from $365M-$375M - TipRanks
CareDx Reports Q2 Non-GAAP EPS of $0.10, Misses Estimates by $0.02, Revenue Down 6.1% Y/Y - AInvest
CareDx Announces Second Quarter 2025 Financial Results - The Globe and Mail
CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation - Lelezard
AlloSure kidney transplant test shows strong predictive value for rejection By Investing.com - Investing.com Nigeria
Pinnacle West Q2 Earnings In Line With Estimates, Revenues Rise Y/Y - The Globe and Mail
CareDx ($CDNA) Is Paying a $20.25M Settlement to Investors — Here’s How to Get Your Share - TradingView
What are the technical indicators suggesting about CareDx IncFree Stock Market Return Analysis - Jammu Links News
What are the latest earnings results for CareDx IncGet alerts on high-potential stock breakouts - Jammu Links News
When is CareDx Inc stock expected to show significant growthStrong return on investment - Jammu Links News
Does CareDx Inc stock perform well during market downturnsDiscover dynamic stocks ready to soar - Jammu Links News
How does CareDx Inc compare to its industry peersAchieve consistent profits with disciplined trading - Jammu Links News
Is CareDx Inc stock overvalued or undervaluedExceptional portfolio growth - Jammu Links News
Should I hold or sell CareDx Inc stock in 2025Invest smarter with advanced market data - Jammu Links News
Why is CareDx Inc stock attracting strong analyst attentionStrongest growth potential - Jammu Links News
How volatile is CareDx Inc stock compared to the marketMaximize your returns with expert insights - Jammu Links News
What analysts say about CareDx Inc stockMaximize gains with data-driven trading alerts - Jammu Links News
What is the dividend policy of CareDx Inc stockFree Stock Market Return Analysis - Jammu Links News
What institutional investors are buying CareDx Inc stockTremendous financial leverage - Jammu Links News
Finanzdaten der Caredx Inc-Aktie (CDNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.96%
1.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):